Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -110.2%. (2004–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $22008 | $46583 | $42350 | $796390 | $1M | $330924 | $28M | — | — | — |
| Enterprise Value | $888176 | $-5358844 | $908518 | $551482 | $-306791 | $2M | $30M | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | 0.03 | — | — | — | 4.41 | 917.02 | — | — | — |
| P/B Ratio | 0.01 | 0.00 | 0.01 | 0.18 | 0.32 | 0.14 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -3.93 | — | — | — | 29.77 | 978.30 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.7% | 86.7% | — | — | — | 100.0% | -3034.5% | — | — | — |
| Operating Margin | -956.9% | -956.9% | — | — | — | -18727.9% | -22305.5% | — | — | — |
| Net Profit Margin | -874.3% | -874.3% | — | — | — | -17932.4% | -29765.9% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -110.2% | -110.2% | -261.1% | -485.1% | -1104.5% | -572.2% | — | -14.2% | — | — |
| ROA | -82.9% | -82.9% | -125.8% | -266.1% | -511.9% | -380.7% | -3879.5% | -1.4% | -343.2% | 5642.7% |
| ROIC | -114.5% | -114.5% | -171.3% | -474.9% | -735.8% | -2118.9% | — | — | — | — |
| ROCE | -116.1% | -116.1% | -212.2% | -397.0% | -701.9% | -351.1% | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.36 | 0.28 | 0.46 | 1.74 | — | 9.73 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | 0.89 | — | 0.04 |
| Net Debt / Equity | — | -0.30 | 0.22 | -0.06 | -0.39 | 0.81 | — | 9.70 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | 0.89 | — | 0.04 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | 0.06 |
| Interest Coverage | -18.11 | -18.11 | -26.29 | -196.49 | -171.03 | -70.87 | -60.79 | — | — | — |
Net cash position: cash ($6M) exceeds total debt ($268875)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.16 | 4.16 | 0.23 | 0.59 | 1.81 | 0.79 | 0.04 | 0.00 | 0.22 | 0.00 |
| Quick Ratio | 4.16 | 4.16 | 0.23 | 0.59 | 1.81 | 0.79 | 0.04 | 0.00 | 0.22 | 0.00 |
| Cash Ratio | 3.59 | 3.59 | 0.12 | 0.49 | 1.75 | 0.79 | 0.04 | 0.00 | 0.22 | 0.00 |
| Asset Turnover | — | 0.07 | — | — | — | 0.01 | 0.10 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 1.97 | — | — | — | — | 258.51 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 74.7% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 74.7% | 0.0% | — | — | — |
| Shares Outstanding | — | $4M | $2M | $26M | $14M | $1M | $20M | $11M | $1863 | $1863 |
Insufficient cash runway
As reported in recent financial statements, the company's operating margin of -956.94% highlights a profound disconnect between current revenue generation and the heavy research expenditures required to advance its pipeline, suggesting that earning power remains non-existent until clinical milestones are achieved and commercialization efforts begin.
The gross margin of 86.75% is an accounting artifact of licensing income rather than a reflection of sustainable product profitability. Investors should monitor whether these margins compress as the company transitions toward the high variable costs associated with cell therapy manufacturing and cold-chain logistics.
Based on historical data, the company's ROIC has consistently remained in negative territory, reaching -23.7% in 2026Q1, which indicates that the firm is currently destroying invested capital rather than compounding it as it navigates the high-risk, pre-commercial phase of its biotechnology development cycle.
The persistent negative returns on capital are driven by the lack of operational scale and the necessity of continuous R&D investment. This trend warrants further investigation into whether management can achieve a pivot toward positive returns once the GEAR platform moves beyond the experimental stage.
According to quarterly filings, the company's DPO has reached extreme levels, exceeding 1800 days in recent periods, which suggests a reliance on extended supplier credit terms to manage liquidity constraints rather than operational efficiency in its working capital management cycle.
The exceptionally high DPO appears to be a defensive measure to preserve cash, yet it may signal potential friction with vendors if payment terms are eventually tightened. The low asset turnover ratio further confirms that the company's current asset base is not yet generating meaningful revenue relative to its size.
As indicated by 2026Q1 filings, the current ratio of 3.25 provides a superficial appearance of liquidity, yet this metric is misleading given the company's high cash burn rate and the limited $5.67M in cash reserves available to fund ongoing clinical development activities.
The liquidity position appears vulnerable under stress, as the company lacks a stable, recurring revenue stream to offset its quarterly operating losses. Investors should monitor the cash runway closely, as the current balance sheet structure suggests a high probability of future dilutive financing requirements.
The price-to-book ratio of 0.01 is frequently misapplied to this business model, as it fails to account for the massive accumulated deficit and the intangible nature of the company's intellectual property, which are not captured by traditional book value metrics in a pre-revenue biotech context.
Using P/B to assess value in this instance obscures the reality that the company's true value lies in its pipeline potential rather than its tangible assets. Analysts should instead focus on cash runway and the probability-weighted net present value of clinical assets to better gauge the firm's fundamental worth.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying COEPW stock.
Coeptis Therapeutics Holdings, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Coeptis Therapeutics Holdings, Inc.'s return on equity (ROE) is -110.2%. The historical average is -217.7%.
Based on historical data, Coeptis Therapeutics Holdings, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Coeptis Therapeutics Holdings, Inc. has 86.7% gross margin and -956.9% operating margin.